资讯

Targeted Oncology35 分钟

STRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC

The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining ...